Rosetta Genomics receives final NY approval for its kidney cancer test Rosetta Genomics announced that the New York State Department of Health has given the company final approval for its Rosetta Kidney Cancer Test for testing on patient samples from the State. Rosetta Genomics has been offering its Kidney Cancer Test in New York under conditional approval since December 9, 2013 and now has full approval in all 50 U.S. states. The Kidney Cancer Test is the company's proprietary microRNA-based assay that can classify the four most common kidney tumors: Clear Cell Renal Cell Carcinoma, Papillary RCC, Chromophobe RCC and Oncocytoma. With this final approval, each of Rosetta's cancer testing services now has full New York State approval.
On The Fly: Analyst Upgrade Summary Today's noteworthy upgrades include: CECO Environmental (CECE) upgraded on several positive catalysts at Roth Capital... EMC (EMC) upgraded to Outperform from Market Perform at Bernstein... Fleetmatics (FLTX) upgraded to Overweight from Neutral at Piper Jaffray... NorthStar Asset Management (NSAM) upgraded to Buy from Hold at MLV & Co.... Penn National (PENN) upgraded to Overweight from Neutral at JPMorgan... Rosetta Genomics (ROSG) upgraded to Buy from Hold at Cantor... Ulta Salon (ULTA) upgraded to Buy from Neutral at Nomura... Xcel Energy (XEL) upgraded to Buy from Hold at Argus.